

Chemotherapy-Induced Weakness and Fatigue in Skeletal Muscle: The Role of Oxidative Stress

Laura A.A. Gilliam¹ and Daret K. St. Clair²

Abstract

Significance: Fatigue is one of the most common symptoms of cancer and its treatment, manifested in the clinic through weakness and exercise intolerance. These side effects not only compromise patient's quality of life (QOL), but also diminish physical activity, resulting in limited treatment and increased morbidity. **Recent Advances:** Oxidative stress, mediated by cancer or chemotherapeutic agents, is an underlying mechanism of the drug-induced toxicity. Nontargeted tissues, such as striated muscle, are severely affected by oxidative stress during chemotherapy, leading to toxicity and dysfunction. **Critical Issues:** These findings highlight the importance of investigating clinically applicable interventions to alleviate the debilitating side effects. This article discusses the clinically available chemotherapy drugs that cause fatigue and oxidative stress in cancer patients, with an in-depth focus on the anthracycline doxorubicin. Doxorubicin, an effective anticancer drug, is a primary example of how chemotherapeutic agents disrupt striated muscle function through oxidative stress. **Future Directions:** Further research investigating antioxidants could provide relief for cancer patients from debilitating muscle weakness, leading to improved quality of life. *Antioxid. Redox Signal.* 15, 2543–2563.

Introduction

BY THE END OF 2010, the American Cancer Society expects 1.5 million new cancer cases will be diagnosed (220). Cancer and its treatment compromises quality of life (QOL), an important indicator of patient outcome and survival in numerous cases (e.g., breast, colorectal, melanoma) (163). A component of QOL is patients' perceived fatigue, one of the most common symptoms of cancer and its treatment (182). Fatigue in cancer patients is a multifactorial condition defined by the National Comprehensive Cancer Network as "a common persistent, and subjective sense of tiredness related to cancer or to the treatment for cancer that interferes with usual functioning" (157). This type of fatigue is not relieved by rest, is exhibited by cancer patients through QOL self-assessments (31, 193, 233, 270) and intensified with the aggressiveness of chemotherapy (58, 108, 182, 193).

Pater and Loeb (181) were among the first to show that perceived fatigue is an independent predictor of QOL and survival in cancer patients. Numerous other studies have followed confirming their results (14, 20, 38, 202). A component of perceived fatigue could be a decline in cognitive function. Evaluation of cognitive impairment involves functionality of multiple domains, which include visuospatial skill, memory, language, and motor function (258).

Over half of patients undergoing chemotherapy exhibit cognitive impairment (109), which is associated with patients perceived fatigue (18). This sense of tiredness can persist from 6 months to 2 years following remission, providing insight into the debilitating, and sometimes long-term side effects of cancer and its treatment (120, 132, 149).

While documenting perceived fatigue is useful clinically, it is difficult to discriminate between a sense of tiredness (i.e., perceived fatigue) and physiological fatigue. Physiological fatigue can be divided into two components, central and peripheral fatigue. Central fatigue involves the central nervous system and the inhibition of neurological reflexes. Central fatigue is a factor with cancer (275), however the interaction of central fatigue and chemotherapy is unknown, limiting the discussion of this component further. Peripheral fatigue is muscle specific and involves the loss of muscle function, divided into two components: muscle fatigue and muscle weakness. Muscle fatigue is defined as the loss of force that is reversible by rest, while muscle weakness is an impaired ability to generate force and is not relieved by rest (177a). Based on available data, this review will discuss the effects of chemotherapy on muscle weakness.

Previous studies have used performance assessments to document muscle weakness in cancer patients that have received chemotherapy. Compared to healthy controls, patients

¹Department of Physiology and ²Graduate Center for Toxicology, University of Kentucky, Lexington, Kentucky.

show a slower chair-rise time, indicating a decrease in muscle strength (25, 85). Hand-grip force, another measurement of muscle weakness, is decreased in cancer patients (25, 96, 230, 231, 269). These studies point to a prominent clinical problem of debilitating muscle weakness with cancer treatment.

One underlying mechanism of the muscle weakness experienced by chemotherapy-treated patients is a developed state of oxidative stress, defined in this review as a disruption of redox signaling and control (112). Numerous chemotherapeutic agents directly or indirectly produce a state of oxidative stress. Drugs that include a quinone moiety in their chemical structure can directly produce a state of oxidative stress by interacting with molecular oxygen and undergoing redox cycling, leading to the generation of reactive oxygen species (ROS) (40). Other chemotherapeutic agents can indirectly produce a state of oxidative stress by decreasing antioxidant levels, crippling the cell's defenses against elevated oxidants (7, 158).

Circulating biomarkers are a nonspecific systemic index of oxidative stress in the body. In cancer patients under going treatment, circulating markers of oxidative stress, in the form of lipid peroxidation and protein carbonyl content, are elevated (44, 91, 105). These markers reflect events of oxidative stress that may exist in various tissues, including skeletal muscle. No current data exist to describe the level of muscle-derived oxidants in cancer patients. However, circulating biomarkers serve as an index about the level of oxidative stress in the body and could signify an elevation in muscle-derived oxidants (201).

In skeletal muscle, exposure to elevated oxidants are known to cause muscle weakness and accelerate the rate of fatigue (191, 235). Antioxidant exposure delays the rate of fatigue, supporting this connection (118, 136, 165). Chemotherapy-induced oxidative stress in cancer patients could be a reflection of the elevated muscle-derived oxidants, an underlying mechanism for the muscle weakness experienced by patients. This article reviews how chemotherapy can affect striated muscle, increasing muscle-derived oxidants and leading to muscle weakness in patients.

Anthracycline Therapy

Numerous chemotherapy drugs have been approved by the Food and Drug Administration to treat patients in the clinic (97). For the purpose of this review we focused on a class of chemotherapy drugs called anthracyclines. For over 50 years, anthracyclines have been used widely in the clinic to treat multiple types of cancers (*e.g.*, leukemia, lymphoma, breast, prostate, ovarian, lung) (see Table 1; (86, 209)). Due to the extensive literature available, the effects of chemotherapy on muscle function are best defined in this class and accessible for evaluation. The mechanisms by which anthracyclines kill tumor cells are various, including: inhibition of DNA replication and RNA transcription, free radical generation leading to DNA damage or lipid peroxidation, DNA alkylation, interference with DNA unwinding or DNA strand separation and helicase activity, and inhibition of topoisomerase II (209). Some or all of these effects are responsible for inhibiting tumor cell growth, preventing division and metastasis. Anthracyclines can also negatively affect noncancerous tissues, including striated muscle, which contributes to the fatigue and muscle weakness in patients treated with anthracycline-based

chemotherapy. A comprehensive literature search over the past 5 years (2005–2010) was performed to document fatigue reports associated with each drug in the anthracycline group (Table 1). Two anthracycline drugs (teniposide and valrubicin) were not included in the table due to the absence of current data documenting associated fatigue with drug administration.

Most studies observing fatigue with anthracycline chemotherapy use the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) to grade the severity of patients perceived fatigue (173a). This method allows reporting of adverse events with descriptive terminology. The grade refers to the severity of the adverse event with a numerical scale: (1) Mild, (2) Moderate, (3) Severe, and (4) Disabling. The adverse event fatigue has specific descriptions associated with the numerical scale: (1) Mild fatigue relieved by rest, (2) Fatigue not relieved by rest—difficulty performing activities of daily life, (3) Fatigue not relieved by rest—interfering with activities of daily life, and (4) Disabling fatigue. In Table 1, each study lists the cancer population and the range of the grades of fatigue associated with the chemotherapy drug. A few studies used a standard QOL questionnaire the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) to report chemotherapy-associated fatigue. This questionnaire has three multi-item symptom scales measuring fatigue and global health status (3, 228). Studies that assessed fatigue using a QOL questionnaire are also included. Table 1 documents the grades of fatigue in cancer patients treated with a specific anthracycline. In studies assessing patient fatigue with anthracycline-based chemotherapy, 47% document grade 4 fatigue, categorized as disabling and effecting physical capabilities of the patients. This table also illustrates that fatigue is a common problem with anthracycline chemotherapy occurring independent of the drug type.

Aside from the antitumor effects, anthracyclines are known to have toxic side effects in normal tissue, including oxidative stress (86). Anthracyclines can generate oxidants through two mechanisms: interaction with the mitochondrial respiratory chain and through a nonenzymatic reaction with ferric iron (103). Numerous drugs in the anthracycline class cause oxidative stress in both humans and rodents.

Elevated oxidants in circulation have been reported in cancer patients following administration of the anthracycline epirubicin (28, 134, 150). Following epirubicin administration in rodents, oxidants are elevated and antioxidants are decreased in both cardiac (54) and hepatic tissue (117). Irinotecan is another example of an anthracycline that causes oxidative stress. Markers of lipid peroxidation are elevated in both plasma and intestines of rodents following irinotecan administration (259, 264). In human breast cancer cells, topotecan exposure causes a decrease in glutathione, along with an increase in lipid peroxidation (7, 243). This drug-induced oxidative stress is a potential mechanism underlying the documented fatigue experienced by cancer patients.

Chemotherapy is generally a combination of drugs administered in a standardized treatment regimen, specific for the cancer type. Various interactive effects of different drugs could occur, leading to collateral damage of nontargeted tissues. The current reductionist approach in the literature provides some clarity on the negative effects of a single chemotherapeutic agent on nontargeted tissues. The

available studies offer valuable information on the drug's mechanism of action and potential interventions that could offset the negative side effects. The next step for the field is to move toward a more clinically relevant approach, in order to directly apply the findings to patients. The existing data focuses on a single chemotherapeutic agent, which provides foundational knowledge about the individual drug and lays the groundwork for future studies in patients. Based on available data involving chemotherapy effects on striated muscle, this review will focus on a single chemotherapy agent, doxorubicin, a representative anthracycline.

Doxorubicin as the Prototype

Doxorubicin is an antibiotic that exerts its antitumor activity by inhibiting DNA Topoisomerase II, thus preventing DNA replication (240). Other antitumor activities of doxorubicin include: generation of ROS leading to DNA damage and apoptotic cell death, stimulation of p53-DNA binding, activation of the caspase cascade, and DNA cross-linking (76, 155). The Farmitalia Research Laboratories of Milan discovered the drug in the early 1960s (11). Since its discovery, doxorubicin has been used widely in the clinic, seen as one of the most effective anticancer drugs (43, 263). Early on in the clinic, reports of doxorubicin causing severe fatigue (174, 175) and affecting cardiac muscle function (124) were documented. Further investigation into the mechanism of the drug revealed elevated oxidants in noncancerous tissues were a likely cause of the cardiotoxicity (40, 49, 60).

Cardiac muscle

Doxorubicin-induced cardiotoxicity is well known in the field of chemotherapy drug research, and has been reviewed widely in the literature (39, 40, 155, 162, 237, 244). The first observations of doxorubicin cardiotoxicity were by Lefrak and colleagues (124). They documented the deterioration of cardiac muscle function by echocardiography, and assessed postmortem cardiac muscle tissue of two patients after doxorubicin administration. Since that first report, numerous studies over the past 30 years have investigated the mechanisms behind doxorubicin-induced cardiotoxicity (237).

The principal mechanism of doxorubicin cardiotoxicity is an increase in oxidative stress, manifested through elevated

oxidants, markers of protein oxidation, and decreased antioxidant activity (39). Elevated oxidant activity is observed in cardiomyocytes following doxorubicin exposure (52, 208, 224, 242, 274). A similar response is observed in rodent cardiac tissue, localized to the mitochondria and sarcoplasmic reticulum (59). This elevation in oxidants comes from multiple sources in the cell. The mitochondria are thought to be the primary source of doxorubicin-induced oxidants (34, 37, 48, 60, 261). Complex I (NADH dehydrogenase) of the electron transport chain is the specific site of doxorubicin reduction, forming an unstable semiquinone (49). The doxorubicin semiquinone is then oxidized to the stable quinone form, transferring an electron to oxygen to produce the superoxide anion (O_2^-) (162).

The elevation of oxidants caused by doxorubicin is protected with the overexpression of mitochondrial specific antioxidants. Figure 1 illustrates how overexpression of manganese superoxide dismutase protects against mitochondrial and myofilament damage caused by doxorubicin (276). Overexpression of other antioxidants such as glutaredoxin 2 (57) and glutathione peroxidase (GpX) (271) also protect against doxorubicin-induced cardiotoxicity, pointing to the involvement of mitochondria.

Other secondary sources of oxidants include NADPH oxidase and altered Fenton chemistry. Doxorubicin-induced oxidant activity was blunted in cardiomyocytes treated with an inhibitor of NADPH oxidase (223). Mice deficient in gp91, a required subunit for NADPH oxidase activity (123), are protected from doxorubicin-induced cardiotoxicity (268). Altered Fenton chemistry occurs during the redox cycling of doxorubicin. During this process aglycone metabolites are produced that alter iron homeostasis, leading to elevated oxidants (155).

Based on its chemical structure, doxorubicin can directly stimulate an increase in oxidants by undergoing redox cycling. However, a secondary, indirect method for doxorubicin to stimulate oxidants is via an inflammatory response. One potential secondary mediator of the inflammatory response is tumor necrosis factor alpha (TNF), a pro-inflammatory cytokine produced by many cell types, including cardiac and skeletal myocytes. Circulating levels of TNF are elevated in cancer, with chemotherapy exacerbating this response (24). Doxorubicin-treated animals and patients exhibit a stress

FIG. 1. Overexpression of the mitochondrial-specific antioxidant MnSOD protects against doxorubicin-induced cardiotoxicity. Electron micrographs of mouse heart 5 days after a single injection of doxorubicin (25 mg/kg). The nontransgenic mouse treated with doxorubicin (control, left) shows variations in mitochondria shape and size, loss of cristae, and exhibits focal swelling. Myofilaments show disarray with loss of Z-bands. The transgenic mouse (transgene, right) that overexpresses human manganese superoxide dismutase (MnSOD) shows uniform mitochondria and intact cardiac myofilaments. Asterisks indicate damaged mitochondria, and M denotes intact mitochondria. The arrow points to intracytoplasmic vacuoles, a nonspecific indicator of cell injury. [From Yen *et al.* (276); reprinted with permission from the American Society of Clinical Investigation].




TABLE 1. FATIGUE SEVERITY ASSOCIATED WITH ANTHRACYCLINE CHEMOTHERAPY OVER THE LAST FIVE YEARS (2005–2010)

<i>Anthracyclines</i>	<i>NCI Common Toxicity Criteria for Adverse Events</i>				<i>QOL Questionnaire</i>
	<i>1</i>	<i>2</i>	<i>3</i>	<i>4</i>	
Daunorubicin Doxorubicin	11 myeloid leukemia patient (232)		41 esophageal cancer patients (101)		
			1,801 breast cancer patients (131) 38 ovarian cancer patients (183)		
		30 heterogeneous cancer patients (247)			
	23 multiple myeloma patients (36)		32 heterogeneous cancer patients (170)		
			162 breast cancer patients (278)		
			67 heterogeneous cancer patients (99) 25 breast cancer patients (279)		
	20 heterogeneous cancer patients (211)				
		38 heterogeneous cancer patients (214)			
	37 heterogeneous cancer patients (53)		26 heterogeneous cancer patients (130)		
			17 thyroid cancer patients (12)		
		48 ovarian cancer patients (185) 28 breast cancer patients (203)			317 endometrial cancer patients (26)
			646 multiple myeloma patients (178)		271 breast cancer patients (128) 151 breast cancer patients (51)

(continued)

TABLE 1. (CONTINUED)

<i>Anthracyclines</i>	NCI Common Toxicity Criteria for Adverse Events				QOL Questionnaire
	1	2	3	4	
Epirubicin	46 prostate cancer patients (22) 24 biliary tract cancer patients (84)				106 lymphoma patients (68)
			12 prostate cancer patients (9)		
	19 heterogeneous cancer patients (65)				25 breast cancer patients (27)
	49 ovarian cancer patients (251)				32 ovarian cancer patients (92)
		44 breast cancer patients (104)			
			37 biliary tract cancer patients (32)		
			24 heterogeneous cancer patients (133)		
	6 breast cancer patients (262)				
		43 NSCLC patients (126)			
			63 breast cancer patients (79)		
Etoposide	60 breast cancer patients (207) 37 gastric cancer patients (171)		46 pancreatic cancer patients (200) 200 breast cancer patients (81)		16 breast cancer patients (121)
			50 breast cancer patients (212)		
		40 bladder cancer patients (246) 19 hepatic cancer patient (280)			
			31 prostate cancer patients (176)		
		39 SCL cancer patients (80)			
	22 lymphoma patients (204)				
			33 SCL cancer patients (266)		
			81 NSCL cancer patients (168) 447 NSCL cancer patients (221) 56 SCL cancer patients (184)		
		32 heterogeneous cancer patients (277)			
			63 SCL cancer patients (153)		
Idarubicin			36 heterogeneous cancer patients (186)		
			41 leukemia patients (114)		

(continued)

TABLE 1. (CONTINUED)

<i>Anthracyclines</i>	<i>NCI Common Toxicity Criteria for Adverse Events</i>				<i>QOL Questionnaire</i>
	1	2	3	4	
Irinotecan		22 heterogeneous cancer patients (77)			
			15 cervical cancer patients (72)		
			21 pancreatic cancer patients (127)		
			51 SCL cancer patients (196)		
			11 NSCL cancer patients (179)		
			39 heterogeneous cancer patients (64)		
			51 small cell lung cancer patients (225)		
			52 head and neck cancer patients (13)		
		28 gastrointestinal cancer patients (239)			
	15 heterogeneous cancer patients (210)		39 esophagogastric cancer patients (70)		
		32 pancreatic cancer patients (177)			
			209 colorectal cancer patients (219)		
			32 glioblastoma patients (194)		
	16 heterogeneous cancer patients (111)				
			57 colorectal cancer patients (116)		
			56 SCL cancer patients (184)		
			68 SCL cancer patients (227)		
				48 NSCL cancer patients (83)	
			84 SCL cancer patients (8)		
			33 SCL cancer patients (222)		
			31 pancreatic cancer patients (90)		
			54 SCL cancer patients (102)		
			51 heterogeneous cancer patients (205)		
			43 NSCL cancer patients (152)		
			46 NSCL cancer patients (161)		
	46 NSCL cancer patients (42)		55 colorectal patients (257)		
	20 colorectal cancer patients (156)				

(continued)

TABLE 1. (CONTINUED)

<i>Anthracyclines</i>	<i>NCI Common Toxicity Criteria for Adverse Events</i>				<i>QOL Questionnaire</i>
	1	2	3	4	
			142 colorectal cancer patients (56) 43 esophagogastric cancer patients (69)		
		48 breast cancer patients (229) 39 NSCL cancer patients (281) 45 heterogeneous cancer patients (216)			
		28 colorectal cancer patients (100)	50 breast cancer patients (82)		
Mixtozantrone		19 prostate cancer patients (35)			
Topotecan		16 heterogeneous cancer patients (47)			
			61 SCL cancer patients (226) 25 heterogeneous cancer patients (265) 37 heterogeneous cancer patients (160)		
			17 SCL cancer patients (180)		
			41 heterogeneous cancer patients (166)		
		22 SCL cancer patients (215)			
			309 SCL cancer patients (66)		
		63 heterogeneous cancer patients (206)			
			38 SCL cancer patients (159)		
			36 heterogeneous cancer patients (186) 21 ovarian cancer patients (23)		

The grade refers to the severity of the adverse event with a numerical scale: (1) Mild, (2) Moderate, (3) Severe, and (4) Disabling. Abbreviations: NCI, National Cancer Institute; NSCL, non-small cell lung; QOL, quality of life; SCL, small cell lung.

response, characterized by an increase in serum levels of inflammatory cytokines, especially TNF (87, 167, 238, 250). Doxorubicin not only stimulates an increase in circulating TNF, but also increases the production of TNF by cardiac muscle (169) and upregulates the TNF receptor subtype 1 (TNFR1) in cardiomyocytes (41). Inhibition of TNF prevents doxorubicin-induced cardiotoxicity and diminishes glutathione depletion and lipid peroxidation (158). TNF is known to elevate ROS in striated muscle (95, 135), mediated through TNFR1 signaling (95). Elevated levels of TNF caused by doxorubicin are an indirect method to increase oxidants and lead to cardiac muscle dysfunction.

This increase in oxidants can modify vital proteins, leading to cardiac muscle dysfunction. Markers of protein oxidation, such as nitrotyrosine and protein carbonylation, are increased in cardiac muscle with doxorubicin exposure (34, 129, 217). Alterations of vital proteins can alter cardiac structure, leading to impaired contractile function. Cardiac tissue exposed to hydrogen peroxide results in altered myofibrillar proteins: troponin I, tropomyosin, actin, and myosin-binding protein-C (16, 30). The post-translational modifications of myofibrillar proteins leads to a decrease in maximal force and compromises cardiac function (16). Oxidative modifications of myofibrillar proteins can alter myofilament structure, resulting in dysfunction of striated muscle.

Doxorubicin can also cause oxidative stress by altering cellular antioxidant expression and activity. In the literature, discrepancies exist between whether doxorubicin inhibits inherent antioxidants, or stimulates an increase in antioxidant activity. In rodent cardiac muscle, data exist in both groups. *In vivo* doxorubicin administration decreases the content of antioxidants: superoxide dismutase (SOD) (93, 158), catalase (CAT) (158), and glutathione (GSH) (106, 125, 158). Activity of SOD is also diminished with doxorubicin (67, 125, 154). These studies hypothesize one mechanism doxorubicin stimulates oxidants is by diminishing cellular antioxidants. However, other studies show an increase in SOD (4, 6, 73), CAT (6, 73, 93, 106, 158), and GpX (4) activities with doxorubicin treatment. These data support the hypothesis of a cellular adaptive response to doxorubicin, elevating antioxidant activity to combat the doxorubicin-induced increase in oxidants.

Studies involving the administration of antioxidants in combination with doxorubicin support oxidant involvement. Rodents administered N-acetylcysteine (NAC) before doxorubicin exposure were protected from doxorubicin-induced cardiotoxicity and myocardial lesions (61). The same results were observed in a canine model of doxorubicin treatment (97). NAC is a nonspecific reduced thiol donor that increases muscle cysteine and GSH availability (78). Doxorubicin is known to decrease GSH content (106, 125, 158), a vital antioxidant in striated muscle. Infusion of glutathione prevented the cardiac contractile impairment caused by doxorubicin (256). Other antioxidants also protect cardiac muscle function in doxorubicin-induced cardiotoxicity. Vitamin E, a lipid soluble antioxidant, protected against doxorubicin-induced left ventricular dysfunction (195) and prevented elevated oxidant activity (19).

Cardiotoxicity limits the amount of doxorubicin given in the clinic (43, 236). However, on this limited dose, numerous reports show patients receiving doxorubicin-based chemotherapy experience debilitating fatigue, often in the moderate to severe category (Table 1). This persistence of weakness

indicates that other striated muscles, involved in exercise and daily activity, may be affected.

Skeletal muscle

Individual case reports document physician-observed lower extremity muscle weakness in patients undergoing doxorubicin-based chemotherapy (94, 110). Schwartz documented weakness and fatigue in breast cancer patients through four cycles of doxorubicin chemotherapy (213). Following doxorubicin exposure, patients exhibited a decline in functional ability (12 min walk test) and a rapid increase in fatigue (Visual analogue scale). Weakness and fatigue are evident 1–5 years after doxorubicin exposure in lymphoma and leukemia patients (68, 248, 255). These studies suggest skeletal muscle weakness caused by doxorubicin exposure.

Existing studies in both rodents and humans show the negative effects of doxorubicin on skeletal muscle. The toxicity of doxorubicin is used in the clinic for the treatment of blepharospasm and cervical dystonia, causing permanent muscle necrosis in patients. Direct injection of doxorubicin into skeletal muscle causes loss of muscle mass, altered myofilament structure and depressed force in rodents (45, 46, 74, 75, 139–143, 145), nonhuman primates (138, 139, 144, 146), and patients (147, 267). Doxorubicin is also administered through isolated limb perfusion in patients with limb sarcoma tumors. This therapy leads to loss of limb muscle function and reduction in size of both Type 1 and Type 2 muscle fibers (21). Pfeiffer and associates used a canine model of isolated limb perfusion with doxorubicin, observing a significant increase in doxorubicin concentrations in the quadriceps, along with muscle atrophy and weakness (187).

Rodent models of systemic doxorubicin treatment consistently reveal a negative affect of doxorubicin on skeletal muscle function. The few studies in the field use an intraperitoneal route of administration for doxorubicin, adapted from the cardiac literature and related to clinical treatment of advanced ovarian cancer or peritoneal carcinomatosis (234, 252). Doroshov and colleagues observed skeletal muscle loss of myofibrillar organization and interstitial edema following a single intraperitoneal injection of doxorubicin (62). This method results in skeletal muscle toxicity exhibited by nucleolar segregation and altered distribution of the perinucleolar chromatin in hindlimb skeletal muscle (151, 254).

Doxorubicin also causes a catabolic response leading to the loss of muscle mass. Patients undergoing doxorubicin-based chemotherapy show loss of muscle mass (21, 245). The skeletal muscle atrophy induced by doxorubicin is thought to occur through the upregulation of the E3 ubiquitin-ligase atrogin1/MAFbx, suggesting catabolism through the proteasome pathway (273). Doxorubicin is a known stimulator of apoptosis in cardiac myocytes (237), with possible similar effects on skeletal muscle that could contribute to catabolism. Apoptosis is induced in C2C12 myotubes following exposure to doxorubicin *in vitro* (98). Oxidant-mediated apoptosis is a common signaling pathway in skeletal muscle atrophy, leading to caspase activation and proteolysis (15). In striated muscle, doxorubicin stimulates both the formation of ROS (242) and activation of caspases (261), which could be linked to apoptotic signaling pathways. We have documented significant loss of muscle mass in both hindlimb (87) and respiratory muscle (88) following doxorubicin treatment.

In vitro contractile function preparations have been used to determine the negative effects of doxorubicin on skeletal muscle function. Daily injections of a low dose of doxorubicin (1.15 mg/kg) depressed hindlimb muscle force, both fast-twitch and slow-twitch muscles, 4 weeks following exposure (71) (Fig. 2). The authors hypothesized the loss of force was associated with a decrease in the muscle-specific isoform of SERCA, an effect on calcium homeostasis (71). We have shown a single injection of doxorubicin depresses force of hindlimb and respiratory muscles (Fig. 3) (87). Most recently, we established a model of doxorubicin-chemotherapy using an intravenous injection, a method commonly used in the clinic (33, 43). Our studies conclude that doxorubicin causes respiratory muscle dysfunction, despite the route of administration (88).




FIG. 2. Doxorubicin depresses skeletal muscle force. Hindlimb muscles were obtained from rats 15 days after daily injections of doxorubicin (1.15 mg/kg/day). Muscles were placed in a tissue bath and isometric contraction measurements were made with a force transducer. Doxorubicin depressed force (N/cm²) in both the EDL (**A**) and soleus (**B**) muscles. Open symbols represent the doxorubicin group, closed symbols represent the saline injected controls ($n=6-9$ muscles for each group). Data are mean \pm SEM. ^a $p < 0.05$, ^b $p < 0.01$ vs. control. [From Ertunc *et al.* (71); reprinted with permission from S. Karger AG, Basel].




FIG. 3. A single injection of doxorubicin depresses force in hindlimb and respiratory muscles. Figure depicts data replotted from recent reports (87, 88) and unpublished observations (L.A. Gilliam). Maximal specific force (N/cm², Po) of soleus (open bars), EDL (hatched bars), and diaphragm (solid bars) was measured 72 h following a single injection of doxorubicin (20 mg/kg) via an intraperitoneal (left) or intravenous (right) injection ($n=3-11$ per muscle). Data expressed as a percent change of experimental control. Mean values shown \pm SEM; * $p < 0.01$.

Studies have shown doxorubicin accumulates in skeletal muscle up to 24 h following administration (62, 187). This accumulation of doxorubicin in the muscle suggests a direct effect of doxorubicin on skeletal muscle function, however the data are divided. *In vitro* doxorubicin experiments have been conducted using varying concentrations of the drug (1–175 μ M). van Norren and colleagues observed a depression in absolute force and an accelerated rate of fatigue in intact hindlimb muscles exposed to doxorubicin (253). They observed a dose-dependent depression in force, with impaired relaxation. Parallel experiments using lower doxorubicin bath concentrations (2 μ M), similar to serum levels found in patients (55, 188), found no change in skeletal muscle force (87, 89).

Studies utilizing permeabilized skeletal muscle fibers have observed how direct doxorubicin exposure alters calcium homeostasis. Doxorubicin increases the rate of tension development in calcium-activated fibers (50, 282). The doxorubicin-induced tension development is blunted by ruthenium red, an inhibitor of the ryanodine receptor, suggesting doxorubicin alters calcium availability. Isolated skeletal muscle sarcoplasmic reticuli exposed to doxorubicin show increased calcium release (241, 282). This is in agreement with another study showing increased calcium influx in C2C12 myotubes exposed to doxorubicin (253). The data suggests doxorubicin acts similar to caffeine, sensitizing the ryanodine receptor to activation calcium, and stimulating calcium release from the SR (5, 282). Intact single fibers exposed to doxorubicin show an increase in tetanic intracellular calcium that does not alter tetanic force (87). These studies investigating doxorubicin-induced skeletal muscle dysfunction establish a negative effect at the molecular level that could be related to weakness in patients undergoing chemotherapy.

One potential mechanism of doxorubicin-induced skeletal muscle dysfunction is an induced state of oxidative stress, similar to cardiac muscle. Few studies exist that analyze

doxorubicin-induced oxidative stress in skeletal muscle. We have shown doxorubicin increases oxidant activity in skeletal muscle, along with markers of protein oxidation (88). Multiple sources where oxidants are produced exist in skeletal muscle, including the mitochondrial electron transport chain, NADPH oxidase, and phospholipase A₂ (78, 107, 191). Yamada and colleagues showed a decrease in complex I activity in isolated mitochondria from skeletal muscle following multiple low dose doxorubicin injections (272).

Similar to cardiac muscle, elevated TNF levels caused by doxorubicin can lead to increased oxidants and muscle weakness in skeletal muscle. Exposure to TNF depresses both respiratory and hindlimb skeletal muscle force (95, 198), shown to be mediated through TNFR1 (95). The accepted mechanism by which TNF mediates contractile dysfunction is through elevated ROS (95). Pretreating with Trolox, a hydrophilic antioxidant, can prevent TNF-induced contractile dysfunction (95). Taken together, these results suggest that elevated levels of TNF caused by doxorubicin could exert an additive oxidant effect, leading to skeletal muscle dysfunction. We have shown TNFR1 signaling is required for doxorubicin-induced muscle weakness in both respiratory and hindlimb muscle (87, 89). TNF mediates the majority of signaling through TNFR1, leading to the activation of cytotoxic cascades and elevated ROS (95, 260). Increased levels of TNF following doxorubicin exposure lead to an additive oxidant effect, contributing to doxorubicin-induced muscle weakness.

In skeletal muscle, elevated oxidants are known to cause muscle weakness and accelerate fatigue, reviewed previously (191, 218, 235). Exposure to high concentrations of exogenous oxidants results in muscle weakness (10, 29, 122, 173, 189, 190). The rate of fatigue is slowed with antioxidant exposure, suggesting a prominent role for oxidants (119, 164, 165, 197). In a state of oxidative stress, redox-sensitive proteins can be modified, altering signaling and contractile function. Exposing myofibrillar proteins, such as myosin and actin, to oxidants can result in modifications that alter protein structure and formation, and decrease force generation (17, 115, 192).

How doxorubicin effects skeletal muscle function is an emerging field. Based on the cardiac literature and current pool of data, the expected underlying mechanism is oxidative stress, occurring via a two-fold pathway (Fig. 4). Doxorubicin can directly stimulate ROS production through redox cycling, or indirectly via TNF-signaling. These two mediators, ROS and TNF, can then lead to the negative effects of doxorubicin on skeletal muscle function. The documented weakness in cancer patients undergoing chemotherapy is a significant clinical problem, welcoming studies for interventions to alleviate these severe side effects.

Future Studies

The emerging field of skeletal muscle dysfunction with chemotherapy warrants further investigation. The majority of reports in the literature document perceived fatigue through patient self-report or physician observations. Only a few studies use quantitative measures to show a decrease in muscle strength (21, 142, 230, 267). The process by which chemotherapy drugs elevate oxidants and cause weakness is also undefined. Documentation of skeletal muscle weakness, along with the mechanism involved, are required.




FIG. 4. Hypothesized pathways for doxorubicin-induced weakness in skeletal muscle. Illustration depicts the two proposed mediators, ROS and TNF, along with hypothesized downstream signaling involved in mediating muscle weakness caused by doxorubicin. ROS, reactive oxygen species; TNF, tumor necrosis factor- α ; TNFR1, TNF receptor subtype 1.

Translational studies are needed to investigate interventions that would prevent the debilitating weakness and fatigue with chemotherapy. The majority of chemotherapy drugs administered cause oxidative stress in noncancerous tissues, making antioxidant interventions attractive. A recent study published in this journal showed that a cysteine-rich protein diet increased muscle strength (hand-grip force) and quality of life in patients undergoing chemotherapy (245). Control comparisons were made with patients receiving an alternative protein diet that was equal in protein content with only minimal quantities of cysteine, indicating a possible antioxidant effect. Cysteine availability is vital in maintaining adequate glutathione levels, an important cellular antioxidant. Cysteine is the rate-limiting step in glutathione synthesis, an amino acid that can replenish loss of glutathione caused by doxorubicin (4, 106, 113). Rodent studies utilizing the antioxidant NAC also support antioxidant therapy. Pretreatment with NAC prevented loss of body weight and cardiotoxicity caused by doxorubicin (61, 97). NAC could also benefit skeletal muscle dysfunction caused by chemotherapy. In healthy individuals, NAC promotes endurance, improving exercise performance, and slowing the rate of fatigue (136, 137, 148, 199). A few studies published in the early 1980s assessed NAC protection against doxorubicin-induced cardiomyopathy in patients. Dresdale and associates administered NAC to disease-free cancer patients with documented doxorubicin-induced cardiomyopathy (63). NAC did not reverse the abnormal cardiac function in patients, administered

over 2 years following chemotherapy. The acute and chronic cardiotoxicity caused by doxorubicin, evident by an increase in tubular area and mitochondrial damage, was not protected with NAC (172, 249). These early studies did not address the timing or dose dependency of NAC, necessitating further studies of the drug, possibly with interventions given pre-chemotherapy exposure.

NAC is not the only antioxidant available to use as a research tool. Further research investigating antioxidants already approved for human use could provide relief for cancer patients from debilitating muscle weakness. An emerging field is developing that requires more systematic testing. As shown in Table 1, patients report fatigue while exposed to multiple different chemotherapeutic agents within the anthracycline class. Fatigue and weakness are common side effects in cancer treatment. These debilitating side effects not only compromise quality of life in patients, but also limit the effectiveness of the treatment. Studies investigating the mechanistic link between chemotherapy-induced oxidative stress and muscle dysfunction lay the groundwork for the development of novel therapies that can lead to improved quality of life and increased physical activity in patients.

Acknowledgments

The authors thank Erin Wolf for editorial assistance. Our work in this area is supported by the National Institutes of Health Grant R01CA139843 (to D.K. St. Clair) and by the American Heart Association Predoctoral Fellowship 09PRE2020088 (to L.A.A. Gilliam).

References

- 1–2. These references have been deleted.
3. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 85: 365–376, 1993.
4. Abd El-Gawad HM and El-Sawalhi MM. Nitric oxide and oxidative stress in brain and heart of normal rats treated with doxorubicin: Role of aminoguanidine. *J Biochem Mol Toxicol* 18: 69–77, 2004.
5. Abramson JJ, Buck E, Salama G, Casida JE, and Pessah IN. Mechanism of anthraquinone-induced calcium release from skeletal muscle sarcoplasmic reticulum. *J Biol Chem* 263: 18750–18758, 1988.
6. Adachi T, Nagae T, Ito Y, Hirano K, and Sugiura M. Relation between cardiotoxic effect of adriamycin and superoxide anion radical. *J Pharmacobiodyn* 6: 114–123, 1983.
7. Akbas SH, Timur M, and Ozben T. The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells. *J Surg Res* 125: 49–55, 2005.
8. Akerley W, McCoy J, Hesketh PJ, Goodwin JW, Bearden JD, Atkins JN, Chansky K, Crowley JJ, and Gandara DR. Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119. *J Thorac Oncol* 2: 526–530, 2007.
9. Amato RJ and Sarao H. A phase I study of paclitaxel/doxorubicin/thalidomide in patients with androgen-independent prostate cancer. *Clin Genitourin Cancer* 4: 281–286, 2006.
10. Andrade FH, Reid MB, Allen DG, and Westerblad H. Effect of hydrogen peroxide and dithiothreitol on contractile function of single skeletal muscle fibres from the mouse. *J Physiol Online* 509: 565–575, 1998.
11. Arcamone F FG and Penco S. Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives. *US Patent* 3,803,124, 1974.
12. Argiris A, Agarwala SS, Karamouzis MV, Burmeister LA, and Carty SE. A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. *Invest New Drugs* 26: 183–188, 2008.
13. Argiris A, Buchanan A, Brockstein B, Kolesar J, Ghebremichael M, Pins M, Hahn K, Axelrod R, and Forastiere A. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: A phase 2 trial of the Eastern Cooperative Oncology Group. *Cancer* 115: 4504–4513, 2009.
14. Arndt V, Stegmaier C, Ziegler H, and Brenner H. A population-based study of the impact of specific symptoms on quality of life in women with breast cancer 1 year after diagnosis. *Cancer* 107: 2496–2503, 2006.
15. Arthur PG, Grounds MD, and Shavlakadze T. Oxidative stress as a therapeutic target during muscle wasting: considering the complex interactions. *Curr Opin Clin Nutr Metab Care* 11: 408–416, 2008.
16. Avner BS, Hinken AC, Yuan C, and Solaro RJ. H₂O₂ alters rat cardiac sarcomere function and protein phosphorylation through redox signaling. *Am J Physiol Heart Circ Physiol* 299: H723–730, 2010.
17. Barreiro E and Hussain SN. Protein carbonylation in skeletal muscles: Impact on function. *Antioxid Redox Signal* 12: 417–429, 2010.
18. Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, and Ryan CM. Cognitive impairment associated with adjuvant therapy in breast cancer. *Psychooncology* 15: 422–430, 2006.
19. Berthiaume JM, Oliveira PJ, Fariss MW, and Wallace KB. Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction. *Cardiovasc Toxicol* 5: 257–267, 2005.
20. Blazeby JM, Brookes ST, and Alderson D. The prognostic value of quality of life scores during treatment for oesophageal cancer. *Gut* 49: 227–230, 2001.
21. Bonifati DM, Ori C, Rossi CR, Caira S, Fanin M, and Angelini C. Neuromuscular damage after hyperthermic isolated limb perfusion in patients with melanoma or sarcoma treated with chemotherapeutic agents. *Cancer Chemother Pharmacol* 46: 517–522, 2000.
22. Borden LS, Jr., Clark PE, Lovato J, Hall MC, Stindt D, Harmon M, Mohler R, and Torti FM. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. *Cancer* 107: 1093–1100, 2006.
23. Bos AM, De Vos FY, de Vries EG, Beijnen JH, Rosing H, Mourits MJ, van der Zee AG, Gietema JA, and Willemse PH. A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. *Eur J Cancer* 41: 539–548, 2005.
24. Bower JE, Ganz PA, Aziz N, and Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. *Psychosom Med* 64: 604–611, 2002.
25. Brown DJ, McMillan DC, and Milroy R. The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. *Cancer* 103: 377–382, 2005.

26. Bruner DW, Barsevick A, Tian C, Randall M, Mannel R, Cohn DE, Sorosky J, and Spirtos NM. Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: A gynecologic oncology group study. *Qual Life Res* 16: 89–100, 2007.
27. Byar KL, Berger AM, Bakken SL, and Cetak MA. Impact of adjuvant breast cancer chemotherapy on fatigue, other symptoms, and quality of life. *Oncol Nurs Forum* 33: E18–26, 2006.
28. Cadeddu C, Piras A, Mantovani G, Deidda M, Dessi M, Madeddu C, Massa E, and Mercuro G. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. *Am Heart J* 160: 487 e1–7, 2010.
29. Callahan LA, She ZW, and Nosek TM. Superoxide, hydroxyl radical, and hydrogen peroxide effects on single-diaphragm fiber contractile apparatus. *J Appl Physiol* 90: 45–54, 2001.
30. Canton M, Neverova I, Menabo R, Van Eyk J, and Di Lisa F. Evidence of myofibrillar protein oxidation induced by postischemic reperfusion in isolated rat hearts. *Am J Physiol Heart Circ Physiol* 286: H870–877, 2004.
31. Cella D, Lai JS, Chang CH, Peterman A, and Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. *Cancer* 94: 528–538, 2002.
32. Cereda S, Passoni P, Reni M, Vigano MG, Aldrighetti L, Nicoletti R, and Villa E. The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma. *Cancer* 116: 2208–2214, 2010.
33. Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P, Hardman JG, Limbird LE, and Gilman AG. *Goodman & Gilman's The pharmacologic basis of therapeutics* New York: McGraw-Hill, Medical Publishing Division; 2001; pp. 1389–1459.
34. Chaiswing L, Cole MP, St Clair DK, Ittarat W, Szweda LI, and Oberley TD. Oxidative damage precedes nitrate damage in adriamycin-induced cardiac mitochondrial injury. *Toxicol Pathol* 32: 536–547, 2004.
35. Chan JS, Beer TM, Quinn DI, Pinski JK, Garzotto M, Sokoloff M, Dehaze DR, and Ryan CW. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. *BJU Int* 102: 1601–1606, 2008.
36. Chanan-Khan A, Miller KC, Musial L, Padmanabhan S, Yu J, Ailawadhi S, Sher T, Mohr A, Bernstein ZP, Barcos M, Patel M, Iancu D, Lee K, and Czuczman MS. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: Results of a phase II clinical trial. *Leuk Lymphoma* 50: 1096–1101, 2009.
37. Chandran K, Aggarwal D, Migrino RQ, Joseph J, McAllister D, Konorev EA, Antholine WE, Zielonka J, Srinivasan S, Avadhani NG, and Kalyanaraman B. Doxorubicin inactivates myocardial cytochrome c oxidase in rats: Cardioprotection by Mito-Q. *Biophys J* 96: 1388–1398, 2009.
38. Chang VT, Thaler HT, Polyak TA, Kornblith AB, Lepore JM, and Portenoy RK. Quality of life and survival: The role of multidimensional symptom assessment. *Cancer* 83: 173–179, 1998.
39. Chatterjee K, Zhang J, Honbo N, and Karliner JS. Doxorubicin cardiomyopathy. *Cardiology* 115: 155–162, 2009.
40. Chen Y, Jungsuwadee P, Vore M, Butterfield DA, and St Clair DK. Collateral damage in cancer chemotherapy: Oxidative stress in nontargeted tissues. *Mol Interv* 7: 147–156, 2007.
41. Chiosi E, Spina A, Sorrentino A, Romano M, Sorvillo L, Senatore G, D'Auria R, Abbruzzese A, Caraglia M, Naviglio S, and Illiano G. Change in TNF-alpha receptor expression is a relevant event in doxorubicin-induced H9c2 cardiomyocyte cell death. *J Interferon Cytokine Res* 27: 589–597, 2007.
42. Choong NW, Mauer AM, Hoffman PC, Rudin CM, Winegarden JD, 3rd, Villano JL, Kozloff M, Wade JL, 3rd, Sciorino DF, Szeto L, and Vokes EE. Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. *J Thorac Oncol* 1: 245–251, 2006.
43. Chu E and DeNita VT. *Physician's Cancer Chemotherapy Drug Manual* Sudbury, MA: Jones & Bartlett Publishers, Inc.; 2008.
44. Crohns M, Liippo K, Erhola M, Kankaanranta H, Moilanen E, Alho H, and Kellokumpu-Lehtinen P. Concurrent decline of several antioxidants and markers of oxidative stress during combination chemotherapy for small cell lung cancer. *Clin Biochem* 42: 1236–1245, 2009.
45. Cullu E, Ozkan I, Culhaci N, and Alparslan B. A comparison of the effect of doxorubicin and phenol on the skeletal muscle. May doxorubicin be a new alternative treatment agent for spasticity? *J Pediatr Orthop B* 14: 134–138, 2005.
46. Cullu E, Ozkan I, Culhaci N, Alparslan B, Dikicioglu E, and Savk SO. [Doxorubicin-induced chemomyectomy effects in rat skeletal muscle]. *Acta Orthop Traumatol Turc* 37: 323–329, 2003.
47. Curtis KK, Hartney JT, Jewell RC, Park JW, Lebowitz PF, Griffin PP, Borad MJ, Fitch TR, and Northfelt DW. A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m² administered weekly as a 30-minute intravenous infusion in patients with cancer. *J Clin Pharmacol* 50: 268–275, 2010.
48. Danz ED, Skramsted J, Henry N, Bennett JA, and Keller RS. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. *Free Radic Biol Med* 46: 1589–1597, 2009.
49. Davies KJ and Doroshov JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. *J Biol Chem* 261: 3060–3067, 1986.
50. de Beer EL, Finkle H, Voest EE, Van Heijst BGV, and Schiereck P. Doxorubicin interacts directly with skinned single skeletal muscle fibres. *Eur J Pharmacol* 214: 97–100, 1992.
51. de Jong N, Kester AD, Schouten HC, Abu-Saad HH, and Courtens AM. Course of fatigue between two cycles of adjuvant chemotherapy in breast cancer patients. *Cancer Nurs* 29: 467–477, 2006.
52. DeAtley SM, Aksenov MY, Aksenova MV, Harris B, Hadley R, Cole HP, Carney JM, and Butterfield DA. Antioxidants protect against reactive oxygen species associated with adriamycin-treated cardiomyocytes. *Cancer Lett* 136: 41–46, 1999.
53. Dees EC, O'Neil BH, Lindley CM, Collichio F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D, and Orlowski RZ. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. *Cancer Chemother Pharmacol* 63: 99–107, 2008.
54. Delemasure S, Sicard P, Lauzier B, Moreau D, Vergely C, and Rochette L. Acute administration of epirubicin induces myocardial depression in isolated rat heart and production

- of radical species evaluated by electron spin resonance spectroscopy. *J Cardiovasc Pharmacol* 50: 647–653, 2007.
55. Delgado G, Potkul RK, Treat JA, Lewandowski GS, Barter JF, Forst D, and Rahman A. A phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer. *Am J Obstet Gynecol* 160: 812–817; discussion 817–819, 1989.
56. Diaz R, Aparicio J, Molina J, Palomar L, Gimenez A, Ponce J, Segura A, and Gomez-Codina J. Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: A single center experience. *Med Oncol* 23: 347–357, 2006.
57. Diotte NM, Xiong Y, Gao J, Chua BH, and Ho YS. Attenuation of doxorubicin-induced cardiac injury by mitochondrial glutaredoxin 2. *Biochim Biophys Acta* 1793: 427–438, 2009.
58. Donovan KA, Jacobsen PB, Andrykowski MA, Winters EM, Balducci L, Malik U, Kenady D, and McGrath P. Course of fatigue in women receiving chemotherapy and/or radiotherapy for early stage breast cancer. *J Pain Symptom Manage* 28: 373–380, 2004.
59. Doroshow JH and Davies KJ. Comparative cardiac oxygen radical metabolism by anthracycline antibiotics, mitoxantrone, bisantrene, 4'-(9-acridinylamino)-methanesulfonm-anisidide, and neocarzinostatin. *Biochem Pharmacol* 32: 2935–2939, 1983.
60. Doroshow JH and Davies KJ. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. *J Biol Chem* 261: 3068–3074, 1986.
61. Doroshow JH, Locker GY, Ifrim I, and Myers CE. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. *J Clin Invest* 68: 1053–1064, 1981.
62. Doroshow JH, Tallent C, and Schechter JE. Ultrastructural features of adriamycin-induced skeletal and cardiac muscle toxicity. *Am J Pathol* 118: 288–297, 1985.
63. Dresdale AR, Barr LH, Bonow RO, Mathisen DJ, Myers CE, Schwartz DE, d'Angelo T, and Rosenberg SA. Prospective randomized study of the role of N-acetyl cysteine in reversing doxorubicin-induced cardiomyopathy. *Am J Clin Oncol* 5: 657–663, 1982.
64. Dugan E, Truax R, Meadows KL, Blobe GC, Morse MA, Fernando NH, Gockerman JP, Petros WP, and Hurwitz HI. Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors. *Anticancer Res* 29: 5149–5153, 2009.
65. Duran I, Siu LL, Chen EX, Oza AM, Sturgeon J, Chin SF, Brown S, Pond GR, and Nottage M. Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors. *Anticancer Drugs* 17: 81–87, 2006.
66. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizoni A, Poulin R, Preston AJ, Dane G, and Ross G. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. *J Clin Oncol* 25: 2086–2092, 2007.
67. el-Missiry MA, Othman AI, Amer MA, and Abd el-Aziz MA. Attenuation of the acute adriamycin-induced cardiac and hepatic oxidative toxicity by N-(2-mercaptopropionyl) glycine in rats. *Free Radic Res* 35: 575–581, 2001.
68. Elbl L, Vasova I, Tomaskova I, Jedlicka F, Kral Z, Navratil M, Smardova L, Wagnerova B, and Vorlicek J. Cardiopulmonary exercise testing in the evaluation of functional capacity after treatment of lymphomas in adults. *Leuk Lymphoma* 47: 843–851, 2006.
69. Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, and Fuchs CS. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. *Dig Dis Sci* 50: 2218–2223, 2005.
70. Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Earle CC, Kulke MH, Meyerhardt JA, Blaszkowsky LS, Zhu AX, Fidas P, Vincitore MM, Mayer RJ, and Fuchs CS. Weekly docetaxel, cisplatin, and irinotecan (TPC): Results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. *Ann Oncol* 20: 475–480, 2009.
71. Ertunc M, Sara Y, Korkusuz P, and Onur R. Differential contractile impairment of fast- and slow-twitch skeletal muscles in a rat model of doxorubicin-induced congestive heart failure. *Pharmacology* 84: 240–248, 2009.
72. Fabbro M, Gladieff L, Guichard F, El Demery M, Dalenc F, Kerr C, Delannes M, Paraiso D, Pujade-Lauraine E, and Kurtz JE. Phase I study of irinotecan and cisplatin in combination with pelvic radiotherapy in the treatment of locally advanced cervical cancer: A GINECO trial. *Gynecol Oncol* 117: 276–280, 2010.
73. Fadillioglu E, Oztas E, Erdogan H, Yagmurca M, Sogut S, Ucar M, and Irmak MK. Protective effects of caffeic acid phenethyl ester on doxorubicin-induced cardiotoxicity in rats. *J Appl Toxicol* 24: 47–52, 2004.
74. Falkenberg JH, Iaizzo PA, and McLoon LK. Physiological assessment of muscle strength *in vitro* after direct injection of doxorubicin into rabbit sternocleidomastoid muscle. *Mov Disord* 16: 683–692, 2001.
75. Falkenberg JH, Iaizzo PA, and McLoon LK. Muscle strength following direct injection of doxorubicin into rabbit sternocleidomastoid muscle *in situ*. *Muscle Nerve* 25: 735–741, 2002.
76. Fang J, Nakamura H, and Iyer AK. Tumor-targeted induction of oxytress for cancer therapy. *J Drug Target* 15: 475–486, 2007.
77. Fekrazad HM, Verschraegen CF, Royce M, Smith HO, Chyi Lee F, and Rabinowitz I. A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer. *Am J Clin Oncol* 33: 393–397, 2010.
78. Ferreira LF and Reid MB. Muscle-derived ROS and thiol regulation in muscle fatigue. *J Appl Physiol* 104: 853–860, 2008.
79. Findlay B, Tonkin K, Crump M, Norris B, Trudeau M, Blackstein M, Burnell M, Skillings J, Bowman D, Walde D, Levine M, Pritchard KI, Palmer MJ, Tu D, and Shepherd L. A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes. *Ann Oncol* 18: 1646–1651, 2007.
80. Frasci G, Comella P, Carreca I, DeCataldis G, Muci D, Brunetti C, Russo A, Palmeri S, D'Aniello R, Giordano R, D'Aiuto M, and Comella G. Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SI-COG phase II study. *Oncology* 68: 223–229, 2005.
81. Frasci G, D'Aiuto G, Comella P, Thomas R, Botti G, Di Bonito M, De Rosa V, Iodice G, Rubulotta MR, and Comella G. Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: Final

- analysis of a sicog phase III study. *Br J Cancer* 95: 1005–1012, 2006.
82. Frasci G, D'Aiuto G, Thomas R, Comella P, Di Bonito M, Lapenta L, D'Aiuto M, Botti G, Vallone P, De Rosa V, D'Aniello R, Giordano R, and Comella G. Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in anthracycline-paclitaxel-refractory breast cancer patients. *Oncology* 68: 391–397, 2005.
 83. Fukuda M, Soda H, Kinoshita A, Nakamura Y, Nagashima S, Takatani H, Tsukamoto K, Kohno S, and Oka M. Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced non-small-cell lung cancer: A multiinstitutional phase 2 study. *Cancer* 110: 606–613, 2007.
 84. Furuse J, Okusaka T, Funakoshi A, Yamao K, Nagase M, Ishii H, Nakachi K, Ueno H, Ikeda M, Morizane C, Horikawa Y, and Mizuno N. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. *Jpn J Clin Oncol* 36: 552–556, 2006.
 85. Galvao DA, Taaffe DR, Spry N, Joseph D, Turner D, and Newton RU. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: A comprehensive cross-sectional investigation. *Prostate Cancer Prostatic Dis* 12: 198–203, 2009.
 86. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. *Biochem Pharmacol* 57: 727–741, 1999.
 87. Gilliam LA, Ferreira LF, Bruton JD, Moylan JS, Westerblad H, St Clair DK, and Reid MB. Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle. *J Appl Physiol* 107: 1935–1942, 2009.
 88. Gilliam LA, Moylan JS, Ann Callahan L, Sumandea MP, and Reid MB. Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy. *Muscle Nerve* 43: 94–102, 2011.
 89. Gilliam LA, Moylan JS, Ferreira LF, and Reid MB. TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness. *Am J Physiol Lung Cell Mol Physiol* 300: L225–231, 2011.
 90. Goel A, Grossbard ML, Malamud S, Homel P, Dietrich M, Rodriguez T, Mirzoyev T, and Kozuch P. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer. *Anticancer Drugs* 18: 263–271, 2007.
 91. Gupta A, Srivastava S, Prasad R, Natu SM, Mittal B, Negi MP, and Srivastava AN. Oxidative stress in non-small cell lung cancer patients after chemotherapy: Association with treatment response. *Respirology* 15: 349–356, 2010.
 92. Hahn CA, Jones EL, Blivin JL, Sanders LL, Yu D, Dewhirst MW, Secord AA, and Prosnitz LR. Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicin. *Int J Hyperthermia* 21: 349–357, 2005.
 93. Hamza A, Amin A, and Daoud S. The protective effect of a purified extract of *Withania somnifera* against doxorubicin-induced cardiac toxicity in rats. *Cell Biol Toxicol* 24: 63–73, 2008.
 94. Harada Y, Kato S, Komiya H, Shirota T, Mukai K, and Hayashi T. Primary omental gamma/delta T-cell lymphoma involving the central nervous system. *Leuk Lymphoma* 45: 1947–1950, 2004.
 95. Hardin BJ, Campbell KS, Smith JD, Arbogast S, Smith J, Moylan JS, and Reid MB. TNF-alpha acts via TNFR1 and muscle-derived oxidants to depress myofibrillar force in murine skeletal muscle. *J Appl Physiol* 104: 694–699, 2008.
 96. Hayes S, Battistutta D, and Newman B. Objective and subjective upper body function six months following diagnosis of breast cancer. *Breast Cancer Res Treat* 94: 1–10, 2005.
 97. Herman EH, Ferrans VJ, Myers CE, and Van Vleet JF. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. *Cancer Res* 45: 276–281, 1985.
 98. Hilder TL, Carlson GM, Haystead TA, Krebs EG, and Graves LM. Caspase-3 dependent cleavage and activation of skeletal muscle phosphorylase b kinase. *Mol Cell Biochem* 275: 233–242, 2005.
 99. Hockenberry MJ, Hooke MC, Gregurich M, and McCarthy K. Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. *J Pediatr Hematol Oncol* 31: 664–669, 2009.
 100. Hofheinz RD, Gnad-Vogt U, Wein A, Saussele S, Kreil S, Pilz L, Hehlmann R, and Hochhaus A. Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: A phase II study. *Anticancer Drugs* 16: 39–45, 2005.
 101. Honda M, Miura A, Izumi Y, Kato T, Ryotokuji T, Monma K, Fujiwara J, Egashira H, and Nemoto T. Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. *Dis Esophagus* 23: 641–645, 2010.
 102. Hong YS, Lee HR, Park S, Lee SC, Hwang IG, Park BB, Lee J, Ahn JS, Ahn MJ, Lim HY, and Park K. Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer. *Br J Cancer* 95: 1648–1652, 2006.
 103. Horenstein MS, Vander Heide RS, and L'Ecuyer TJ. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. *Mol Genet Metab* 71: 436–444, 2000.
 104. Hurley J, Reis I, Silva O, Gomez C, DeZarraga F, Velez P, Welsh C, Powell J, and Doliny P. Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer. *Clin Breast Cancer* 5: 447–454, 2005.
 105. Il'yasova D, Mixon G, Wang F, Marcom PK, Marks J, Spasojevic I, Craft N, Arredondo F, and DiGiulio R. Markers of oxidative status in a clinical model of oxidative assault: A pilot study in human blood following doxorubicin administration. *Biomarkers* 14: 321–325, 2009.
 106. Iqbal M, Dubey K, Anwer T, Ashish A, and Pillai KK. Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. *Pharmacol Rep* 60: 382–390, 2008.
 107. Jackson MJ, Pye D, and Palomero J. The production of reactive oxygen and nitrogen species by skeletal muscle. *J Appl Physiol* 102: 1664–1670, 2007.
 108. Jacobsen PB, Hann DM, Azzarello LM, Horton J, Balducci L, and Lyman GH. Fatigue in women receiving adjuvant chemotherapy for breast cancer: Characteristics, course, and correlates. *J Pain Symptom Manage* 18: 233–242, 1999.
 109. Jansen CE, Cooper BA, Dodd MJ, and Miaskowski CA. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. *Support Care Cancer*, 2010.

110. Jhamb R, Gupta N, Garg S, Kumar S, Gulati S, Mishra D, and Beniwal P. Diffuse lymphomatous infiltration of kidney presenting as renal tubular acidosis and hypokalemic paralysis: case report. *Croat Med J* 48: 860–863, 2007.
111. Jimeno A, Rudek MA, Purcell T, Laheru DA, Messersmith WA, Dancey J, Carducci MA, Baker SD, Hidalgo M, and Donehower RC. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. *Cancer Chemother Pharmacol* 61: 423–433, 2008.
112. Jones DP. Redefining oxidative stress. *Antioxid Redox Signal* 8: 1865–1879, 2006.
113. Joshi G, Hardas S, Sultana R, St Clair DK, Vore M, and Butterfield DA. Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by *in vivo* administration of adriamycin: Implication for chemobrain. *J Neurosci Res* 85: 497–503, 2007.
114. Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, and Garcia-Manero G. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. *Br J Haematol* 150: 72–82, 2010.
115. Kanski J, Behring A, Pelling J, and Schoneich C. Proteomic identification of 3-nitrotyrosine-containing rat cardiac proteins: Effects of biological aging. *Am J Physiol Heart Circ Physiol* 288: H371–381, 2005.
116. Kato T, Mishima H, Ikenaga M, Murata K, Ishida H, Fukunaga M, Ota H, Tominaga S, Ohnishi T, Amano M, Ikeda K, Ikeda M, Sekimoto M, Sakamoto J, and Monden M. A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. *Cancer Chemother Pharmacol* 61: 275–281, 2008.
117. Kebieche M, Lakroun Z, Lahouel M, Bouayed J, Meraihi Z, and Soulimani R. Evaluation of epirubicin-induced acute oxidative stress toxicity in rat liver cells and mitochondria, and the prevention of toxicity through quercetin administration. *Exp Toxicol Pathol* 61: 161–167, 2009.
118. Kelly MK, Wicker RJ, Barstow TJ, and Harms CA. Effects of N-acetylcysteine on respiratory muscle fatigue during heavy exercise. *Respir Physiol Neurobiol* 165: 67–72, 2009.
119. Khawli FA and Reid MB. N-acetylcysteine depresses contractile function and inhibits fatigue of diaphragm *in vitro*. *J Appl Physiol* 77: 317–324, 1994.
120. Knobel H, Havard Loge J, Brit Lund M, Forfang K, Nome O, and Kaasa S. Late medical complications and fatigue in Hodgkin's disease survivors. *J Clin Oncol* 19: 3226–3233, 2001.
121. Kuo HH, Chiu MJ, Liao WC, and Hwang SL. Quality of sleep and related factors during chemotherapy in patients with stage I/II breast cancer. *J Formos Med Assoc* 105: 64–69, 2006.
122. Lamb GD and Posterino GS. Effects of oxidation and reduction on contractile function in skeletal muscle fibres of the rat. *J Physiol* 546: 149–163, 2003.
123. Lambeth JD. NOX enzymes and the biology of reactive oxygen. *Nat Rev Immunol* 4: 181–189, 2004.
124. Lefrak EA, Pitha J, Rosenheim S, and Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. *Cancer* 32: 302–314, 1973.
125. Li T, Danelisen I, and Singal PK. Early changes in myocardial antioxidant enzymes in rats treated with adriamycin. *Mol Cell Biochem* 232: 19–26, 2002.
126. Lin CM, Chen CH, Chang JW, and Tsao TC. Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy. *Am J Clin Oncol* 32: 169–173, 2009.
127. Lipton A, Campbell-Baird C, Witters L, Harvey H, and Ali S. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. *J Clin Gastroenterol* 44: 286–288, 2010.
128. Liu J, Tu D, Dancey J, Reyno L, Pritchard KI, Pater J, and Seymour LK. Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19. *Breast Cancer Res Treat* 100: 263–271, 2006.
129. Liu L, Zhang XJ, Qian B, Min XY, and Cheng YL. [Heat shock protein 27 attenuated doxorubicin-induced myocardial damage by reducing cardiomyocyte apoptosis, mitochondrial damage and protein carbonylation]. *Zhonghua Xin Xue Guan Bing Za Zhi* 36: 1021–1026, 2008.
130. LoConte NK, Thomas JP, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, and Kolesar J. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. *Cancer Chemother Pharmacol* 63: 109–115, 2008.
131. Loesch D, Greco FA, Senzer NN, Burris HA, Hainsworth JD, Jones S, Vukelja SJ, Sandbach J, Holmes F, Sedlacek S, Pippen J, Lindquist D, McIntyre K, Blum JL, Modiano MR, Boehm KA, Zhan F, Asmar L, and Robert N. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. *J Clin Oncol* 28: 2958–2965, 2010.
132. Luctkar-Flude M, Groll D, Woodend K, and Tranmer J. Fatigue and physical activity in older patients with cancer: A six-month follow-up study. *Oncol Nurs Forum* 36: 194–202, 2009.
133. Mahadevan D, Dreisbach L, Kristedja T, Williams D, Obregon Y, Kurtin S, and Von Hoff DD. Phase I study of fixed dose gemcitabine plus epirubicin in patients with advanced solid malignancies. *Am J Clin Oncol* 32: 607–611, 2009.
134. Mantovani G, Madeddu C, Cadeddu C, Dessi M, Piras A, Massa E, Serpe R, Antoni G, and Mercurio G. Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: Correlation with inflammatory and oxidative stress markers. *Oncologist* 13: 1296–1305, 2008.
135. Mariappan N, Soorappan RN, Haque M, Sriramula S, and Francis J. TNF- α -induced mitochondrial oxidative stress and cardiac dysfunction: Restoration by superoxide dismutase mimetic Tempol. *Am J Physiol Heart Circ Physiol* 293: H2726–H2737, 2007.
136. Matuszczak Y, Farid M, Jones J, Lansdowne S, Smith MA, Taylor AA, and Reid MB. Effects of N-acetylcysteine on glutathione oxidation and fatigue during handgrip exercise. *Muscle Nerve* 32: 633–638, 2005.
137. McKenna MJ, Medved I, Goodman CA, Brown MJ, Bjorksten AR, Murphy KT, Petersen AC, Sostaric S, and Gong X. N-acetylcysteine attenuates the decline in muscle Na⁺, K⁺-pump activity and delays fatigue during prolonged exercise in humans. *J Physiol* 576: 279–288, 2006.

138. McLoon LK, Bauer G, and Wirtschafter J. Quantification of muscle loss in the doxorubicin-treated orbicularis oculi of the monkey. Effect of local injection of doxorubicin into the eyelid. *Invest Ophthalmol Vis Sci* 32: 1667–1673, 1991.
139. McLoon LK, Ekerdt M, and Wirtschafter J. Verapamil substantially increases the chemomyectomy effect of doxorubicin injected into rabbit or monkey eyelid. *Invest Ophthalmol Vis Sci* 33: 3228–3234, 1992.
140. McLoon LK, Falkenberg JH, Dykstra D, and Iaizzo PA. Doxorubicin chemomyectomy as a treatment for cervical dystonia: Histological assessment after direct injection into the sternocleidomastoid muscle. *Muscle Nerve* 21: 1457–1464, 1998.
141. McLoon LK, Kirsch JD, Cameron S, and Wirtschafter JD. Injection of doxorubicin into rabbit eyelid does not result in loss of facial motor neurons. *Brain Res* 641: 105–110, 1994.
142. McLoon LK, Luo XX, and Wirtschafter J. Acute morphologic changes in orbicularis oculi muscle after doxorubicin injection into the eyelid. *Muscle Nerve* 16: 737–743, 1993.
143. McLoon LK, Ozel B, and Wirtschafter J. Cyclosporin protects the eyelid skin from injury after injection of doxorubicin. *Invest Ophthalmol Vis Sci* 36: 1433–1440, 1995.
144. McLoon LK and Wirtschafter J. Doxorubicin chemomyectomy: Injection of monkey orbicularis oculi results in selective muscle injury. *Invest Ophthalmol Vis Sci* 29: 1854–1859, 1988.
145. McLoon LK and Wirtschafter JD. Doxorubicin chemomyectomy in orbicularis oculi: Increasing drug infiltration at the injection site. *Curr Eye Res* 15: 883–889, 1996.
146. McLoon LK and Wirtschafter JD. Doxil-induced chemomyectomy: Effectiveness for permanent removal of orbicularis oculi muscle in monkey eyelid. *Invest Ophthalmol Vis Sci* 42: 1254–1257, 2001.
147. McLoon LK, Wirtschafter JD, and Cameron JD. Muscle loss from doxorubicin injections into the eyelids of a patient with blepharospasm. *Am J Ophthalmol* 116: 646–648, 1993.
148. Medved I, Brown MJ, Bjorksten AR, Murphy KT, Petersen AC, Sostaric S, Gong X, and McKenna MJ. N-acetylcysteine enhances muscle cysteine and glutathione availability and attenuates fatigue during prolonged exercise in endurance-trained individuals. *J Appl Physiol* 97: 1477–1485, 2004.
149. Meeske K, Smith AW, Alfano CM, McGregor BA, McTiernan A, Baumgartner KB, Malone KE, Reeve BB, Ballard-Barbash R, and Bernstein L. Fatigue in breast cancer survivors two to five years post diagnosis: A HEAL Study report. *Qual Life Res* 16: 947–960, 2007.
150. Mercurio G, Cadeddu C, Piras A, Dessi M, Madeddu C, Deidda M, Serpe R, Massa E, and Mantovani G. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: Correlation with inflammatory and oxidative stress markers. *Oncologist* 12: 1124–1133, 2007.
151. Merski J, Daskal Y, and Busch H. Comparison of adriamycin-induced nucleolar segregation in skeletal muscle, cardiac muscle, and liver cells. *Cancer Treat Rep* 62: 771–778, 1978.
152. Miller AA, Case D, Atkins JN, Giguere JK, and Bearden JD. Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer. *J Thorac Oncol* 1: 832–836, 2006.
153. Miller AA, Wang XF, Bogart JA, Hodgson LD, Rocha Lima CM, Radford JE, Vokes EE, and Green MR. Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. *J Thorac Oncol* 2: 645–651, 2007.
154. Mingyan E, Hongli L, Shufeng L, and Bo Y. Effects of pyrrolidine dithiocarbamate on antioxidant enzymes in cardiomyopathy induced by adriamycin in rats. *Cardiology* 111: 119–125, 2008.
155. Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. *Pharmacol Rev* 56: 185–229, 2004.
156. Mita MM, Ochoa L, Rowinsky EK, Kuhn J, Schwartz G, Hammond LA, Patnaik A, Yeh IT, Izbicka E, Berg K, and Tolcher AW. A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. *Ann Oncol* 17: 313–321, 2006.
157. Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, Donnelly J, Eisenberger MA, Escalante C, Hinds P, Jacobsen PB, Kaldor P, Knight SJ, Peterman A, Piper BF, Rugo H, Sabbatini P, and Stahl C. NCCN Practice Guidelines for Cancer-Related Fatigue. *Oncology (Williston Park)* 14: 151–161, 2000.
158. Mohamed HE, Asker ME, Ali SI, and el-Fattah TM. Protection against doxorubicin cardiomyopathy in rats: Role of phosphodiesterase inhibitors type 4. *J Pharm Pharmacol* 56: 757–768, 2004.
159. Molina JR, Jett JR, Foster N, Lair BS, Carroll TJ, Tazelaar HD, Hillman S, Mailliard JA, Bernath AM, Jr., and Nikcevich D. Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer. *Am J Clin Oncol* 29: 246–251, 2006.
160. Molina JR, Kaufmann SH, Reid JM, Rubin SD, Galvez-Peralta M, Friedman R, Flatten KS, Koch KM, Gilmer TM, Mullin RJ, Jewell RC, Felten SJ, Mandrekar S, Adjei AA, and Erlichman C. Evaluation of lapatinib and topotecan combination therapy: Tissue culture, murine xenograft, and phase I clinical trial data. *Clin Cancer Res* 14: 7900–7908, 2008.
161. Molina JR, Nikcevich D, Hillman S, Geyer S, Drevyanko T, Jett J, Verdirame J, Tazelaar H, Rowland K, Wos E, Kutteh L, Nair S, Fitch T, Flynn P, Stella P, and Adjei AA. A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer. *Cancer Invest* 24: 382–389, 2006.
162. Monsuez JJ, Charniot JC, Vignat N, and Artigou JY. Cardiac side-effects of cancer chemotherapy. *Int J Cardiol*, 2010.
163. Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: An overview of the literature from 1982 to 2008. *Health Qual Life Outcomes* 7: 102, 2009.
164. Moopanar TR and Allen DG. Reactive oxygen species reduce myofibrillar Ca^{2+} sensitivity in fatiguing mouse skeletal muscle at 37 degrees C. *J Physiol* 564: 189–199, 2005.
165. Moopanar TR and Allen DG. The activity-induced reduction of myofibrillar Ca^{2+} sensitivity in mouse skeletal muscle is reversed by dithiothreitol. *J Physiol* 571: 191–200, 2006.
166. Morris R, Alvarez RD, Andrews S, Malone J, Bryant C, Heilbrun LK, Smith D, Schimp V, and Munkarah A. Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers. *Gynecol Oncol* 109: 346–352, 2008.
167. Morsi MI, Hussein AE, Mostafa M, El-Abd E, and El-Moneim NA. Evaluation of tumour necrosis factor- α ,

- soluble P-selectin, gamma-glutamyl transferase, glutathione S-transferase-pi and alpha-fetoprotein in patients with hepatocellular carcinoma before and during chemotherapy. *Br J Biomed Sci* 63: 74–78, 2006.
168. Movsas B, Langer CJ, Ross HJ, Wang L, Jotte RM, Feigenberg S, Xu F, Huang CH, Monberg MJ, and Obasaju CK. Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer. *J Thorac Oncol* 5: 673–679, 2010.
 169. Mukherjee S, Banerjee SK, Maulik M, Dinda AK, Talwar KK, and Maulik SK. Protection against acute adriamycin-induced cardiotoxicity by garlic: Role of endogenous antioxidants and inhibition of TNF-alpha expression. *BMC Pharmacol* 3: 16, 2003.
 170. Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, and Daud A. Phase I trial of vorinostat and doxorubicin in solid tumours: Histone deacetylase 2 expression as a predictive marker. *Br J Cancer* 101: 1044–1050, 2009.
 171. Murad AM, Skare NG, Vinholes J, Lago S, and Pecego R. Phase II multicenter trial of docetaxel, epirubicin, and 5-fluorouracil (DEF) in the treatment of advanced gastric cancer: A novel, safe, and active regimen. *Gastric Cancer* 9: 99–105, 2006.
 172. Myers C, Bonow R, Palmeri S, Jenkins J, Corden B, Locker G, Doroshow J, and Epstein S. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. *Semin Oncol* 10: 53–55, 1983.
 173. Nashawati E, DiMarco A, and Supinski G. Effects produced by infusion of a free radical-generating solution into the diaphragm. *Am Rev Respir Dis* 147: 60–65, 1993.
 - 173a. National Cancer Institute Common Toxicity Criteria for Adverse Events. 2010.
 174. Neidhart JA, Gochnour D, Roach R, Hoth D, and Young D. A comparison of mitoxantrone and doxorubicin in breast cancer. *J Clin Oncol* 4: 672–677, 1986.
 175. Neidhart JA, Gochnour D, Roach RW, Young D, and Steinberg JA. A comparative trial of mitoxantrone and doxorubicin in patients with minimally pretreated breast cancer. *Semin Oncol* 11: 11–14, 1984.
 176. Neri B, Cipriani G, Fulignati C, Turrini M, Ponchiatti R, Bartoletti R, Della Melina A, Di Cello V, Dominici A, Maleci D, Raugei A, Villari D, and Nicita G. Weekly paclitaxel and epirubicin in the treatment of symptomatic hormone-refractory advanced prostate carcinoma: Report of a phase II trial. *Anticancer Drugs* 16: 63–66, 2005.
 177. Neri B, Cipriani G, Grifoni R, Molinara E, Pantaleo P, Rangan S, Vannini A, Tonelli P, Valeri A, Pantalone D, Taddei A, and Bechi P. Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer. *Oncol Res* 17: 559–564, 2009.
 - 177a. NHLBI Workshop summary. Respiratory muscle fatigue. Report of the Respiratory Muscle Fatigue Workshop Group. *Am Rev Respir Dis* 142: 474–480, 1990.
 178. Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, and Harousseau JL. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression. *J Clin Oncol* 25: 3892–3901, 2007.
 179. Oshita F, Saito H, Murakami S, Kondo T, and Yamada K. Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer. *Am J Clin Oncol* 33: 66–69, 2010.
 180. Park SH, Cho EK, Kim Y, Kyung SY, An CH, Lee SP, Park JW, Jeong SH, Lee JI, Choi SJ, Park J, Shin DB, and Lee JH. Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer. *Cancer Chemother Pharmacol* 62: 1009–1014, 2008.
 181. Pater JL and Loeb M. Nonanatomic prognostic factors in carcinoma of the lung: A multivariate analysis. *Cancer* 50: 326–331, 1982.
 182. Patrick DL, Ferketich SL, Frame PS, Harris JJ, Hendricks CB, Levin B, Link MP, Lustig C, McLaughlin J, Reid LD, Turrisi AT, III, Unutzer J, and Vernon SW. National Institutes of Health State-of-the-Science Conference Statement: Symptom management in cancer: Pain, depression, and fatigue, July 15–17, 2002. *J Natl Cancer Inst Monogr* 9–16, 2004.
 183. Pectasides D, Pectasides E, Papaxoinis G, Psyrris A, Pliarchopoulou K, Koumariou A, Macheras A, Athanasas G, Xiros N, and Economopoulos T. Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma. *Gynecol Oncol* 118: 52–57, 2010.
 184. Pectasides D, Samantas E, Fountzilas G, Briassoulis E, Kosmidis P, Skarlos D, Dimopoulos MA, Kalofonos HP, Economopoulos T, and Syrigos K. Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group. *Lung Cancer* 58: 355–361, 2007.
 185. Pectasides D, Xiros N, Papaxoinis G, Aravantinos G, Sykiotis C, Pectasides E, Psyrris A, Koumariou A, Gaglia A, Gouveris P, and Economopoulos T. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma. *Gynecol Oncol* 108: 47–52, 2008.
 186. Penson RT, Seiden MV, Matulonis UA, Appleman LJ, Fuller AF, Goodman A, Campos SM, Clark JW, Roche M, and Eder JP. A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. *Br J Cancer* 93: 54–59, 2005.
 187. Pfeiffer T, Krause U, Thome U, Rajewski A, Skorzek M, and Scheulen ME. Tissue toxicity of doxorubicin in first and second hyperthermic isolated limb perfusion. An experimental study in dogs. *Eur J Surg Oncol* 23: 439–444, 1997.
 188. Piscitelli SC, Rodvold KA, Rushing DA, and Tewksbury DA. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. *Clin Pharmacol Ther* 53: 555–561, 1993.
 189. Plant DR, Gregorevic P, Williams DA, and Lynch GS. Redox modulation of maximum force production of fast-and slow-twitch skeletal muscles of rats and mice. *J Appl Physiol* 90: 832–838, 2001.
 190. Posterino GS and Lamb GD. Effects of reducing agents and oxidants on excitation-contraction coupling in skeletal muscle fibres of rat and toad. *J Physiol* 496: 809–825, 1996.
 191. Powers SK and Jackson MJ. Exercise-induced oxidative stress: Cellular mechanisms and impact on muscle force production. *Physiol Rev* 88: 1243–1276, 2008.

192. Prochniewicz E, Lowe DA, Spakowicz DJ, Higgins L, O'Connor K, Thompson LV, Ferrington DA, and Thomas DD. Functional, structural, and chemical changes in myosin associated with hydrogen peroxide treatment of skeletal muscle fibers. *Am J Physiol Cell Physiol* 294: C613–626, 2008.
193. Prue G, Allen J, Gracey J, Rankin J, and Cramp F. Fatigue in gynecological cancer patients during and after anticancer treatment. *J Pain Symptom Manage* 39: 197–210, 2010.
194. Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H, de Groot JF, Ritterhouse MG, Ictech SE, and Yung WK. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. *Neuro Oncol* 10: 216–222, 2008.
195. Puri A, Maulik SK, Ray R, and Bhatnagar V. Electrocardiographic and biochemical evidence for the cardioprotective effect of vitamin E in doxorubicin-induced acute cardiotoxicity in rats. *Eur J Pediatr Surg* 15: 387–391, 2005.
196. Ramalingam SS, Foster J, Gooding W, Evans T, Sulecki M, and Belani CP. Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer. *Cancer* 116: 1344–1349, 2010.
197. Reid MB, Haack KE, Franchek KM, Valberg PA, Kobzik L, and West MS. Reactive oxygen in skeletal muscle. I. Intracellular oxidant kinetics and fatigue *in vitro*. *J Appl Physiol* 73: 1797–1804, 1992.
198. Reid MB, Lannergren J, and Westerblad H. Respiratory and limb muscle weakness induced by tumor necrosis factor- α : Involvement of muscle myofilaments. *Am J Respir Crit Care Med* 166: 479–484, 2002.
199. Reid MB, Stokic DS, Koch SM, Khawli FA, and Leis AA. N-acetylcysteine inhibits muscle fatigue in humans. *J Clin Invest* 94: 2468–2474, 1994.
200. Reni M, Cereda S, Bonetto E, Vigano MG, Passoni P, Zerbi A, Balzano G, Nicoletti R, Staudacher C, and Di Carlo V. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. *Cancer Chemother Pharmacol* 59: 361–367, 2007.
201. Rietjens SJ, Beelen M, Koopman R, LJ VANL, Bast A, and Haenen GR. A single session of resistance exercise induces oxidative damage in untrained men. *Med Sci Sports Exerc* 39: 2145–2151, 2007.
202. Ringdal GI, Gotestam KG, Kaasa S, Kvinnsland S, and Ringdal K. Prognostic factors and survival in a heterogeneous sample of cancer patients. *Br J Cancer* 73: 1594–1599, 1996.
203. Rom J, von Minckwitz G, Eiermann W, Sievert M, Schlehe B, Marme F, Schuetz F, Scharf A, Eichbaum M, Sinn HP, Kaufmann M, Sohn C, and Schneeweiss A. Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: Final results of a multicentric phase I study. *Ann Oncol* 19: 1698–1705, 2008.
204. Ruan J, Martin P, Coleman M, Furman RR, Cheung K, Faye A, Elstrom R, Lachs M, Hajjar KA, and Leonard JP. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. *Cancer* 116: 2655–2664, 2010.
205. Ryan DP, O'Neil BH, Supko JG, Rocha Lima CM, Dees EC, Appleman LJ, Clark J, Fidias P, Orlowski RZ, Kashala O, Eder JP, and Cusack JC, Jr. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. *Cancer* 107: 2688–2697, 2006.
206. Safra T, Menczer J, Bernstein R, Shpigel S, Inbar MJ, Girsaru D, Golan A, and Levy T. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. *Gynecol Oncol* 105: 205–210, 2007.
207. Sarid D, Ron IG, Sperber F, Stadler Y, Kahan P, Kovner F, Ben-Yosef R, Marmor S, Grinberg Y, Maimon N, Weinstein J, and Yaal-Hahoshen N. Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: A phase II study. *Clin Drug Investig* 26: 691–701, 2006.
208. Sarvazyan N. Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. *Am J Physiol* 271: H2079–2085, 1996.
209. Sawyer DB, Peng X, Chen B, Pentassuglia L, and Lim CC. Mechanisms of anthracycline cardiac injury: Can we identify strategies for cardioprotection? *Prog Cardiovasc Dis* 53: 105–113, 2010.
210. Sayar H, Shen Z, Lee SJ, Royce M, Rabinowitz I, Lee F, Smith H, Eberhardt S, Maestas A, Lu H, and Verschaegen C. Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies. *Invest New Drugs* 27: 153–158, 2009.
211. Schelman WR, Morgan-Meadows S, Marnocha R, Lee F, Eickhoff J, Huang W, Pomplun M, Jiang Z, Alberti D, Kolesar JM, Ivy P, Wilding G, and Traynor AM. A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors. *Cancer Chemother Pharmacol* 63: 1147–1156, 2009.
212. Schneeweiss A, Schuetz F, Rudlowski C, Hahn M, Lauscher I, Sinn HP, von Fournier D, and Sohn C. Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: Final results of a phase I/II trial. *Anticancer Drugs* 16: 1023–1028, 2005.
213. Schwartz AL, Winters-Stone K, and Gallucci B. Exercise effects on bone mineral density in women with breast cancer receiving adjuvant chemotherapy. *Oncol Nurs Forum* 34: 627–633, 2007.
214. Sessa C, Perotti A, Noverasco C, De Braud F, Gallerani E, Cresta S, Zucchetti M, Vigano L, Locatelli A, Jimeno J, Feilchenfeldt JW, D'Incalci M, Capri G, Ielmini N, and Gianni L. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. *Eur J Cancer* 45: 1153–1161, 2009.
215. Shah C, Ready N, Perry M, Kirshner J, Gajra A, Neuman N, and Garziano S. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. *Lung Cancer* 57: 84–88, 2007.
216. Shah MA, Kortmansky J, Motwani M, Drobnjak M, Gonen M, Yi S, Weyerbacher A, Cordon-Cardo C, Lefkowitz R, Brenner B, O'Reilly E, Saltz L, Tong W, Kelsen DP, and Schwartz GK. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. *Clin Cancer Res* 11: 3836–3845, 2005.
217. Shuai Y, Guo JB, Peng SQ, Zhang LS, Guo J, Han G, and Dong YS. Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosative impairment. *Toxicol Lett* 170: 66–74, 2007.
218. Smith MA and Reid MB. Redox modulation of contractile function in respiratory and limb skeletal muscle. *Respir Physiol Neurobiol* 151: 229–241, 2006.
219. Sobrero A, Ackland S, Clarke S, Perez-Carrion R, Chiara S, Gapski J, Mainwaring P, Langer B, and Young S. Phase IV study of bevacizumab in combination with infusional

- fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. *Oncology* 77: 113–119, 2009.
220. Society AC. Cancer Facts & Figures 2010. In: *Atlanta: American Cancer Society*. 2010.
221. Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Blakely J, Serwatowski P, Karaseva NA, Ciuleanu T, Jassem J, Dediu M, Hong S, Visseren-Grul C, Hanauske AR, Obasaju CK, Guba SC, and Thatcher N. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naïve patients with extensive-stage small-cell lung cancer. *J Clin Oncol* 27: 4787–4792, 2009.
222. Sohn JH, Moon YW, Lee CG, Kim GE, Chung KY, Chang J, Kim SK, Kim YS, Choi BW, Choi HJ, and Kim JH. Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer. *Cancer* 109: 1845–1950, 2007.
223. Spallarossa P, Altieri P, Garibaldi S, Ghigliotti G, Barisione C, Manca V, Fabbi P, Ballestrero A, Brunelli C, and Barsotti A. Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. *Cardiovasc Res* 69: 736–745, 2006.
224. Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, Rossettin P, Ghigliotti G, Ballestrero A, Patrone F, Barsotti A, and Brunelli C. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes *in vitro*. *J Mol Cell Cardiol* 37: 837–846, 2004.
225. Spigel DR, Greco FA, Zubkus JD, Murphy PB, Saez RA, Farley C, Yardley DA, Burris HA, 3rd, and Hainsworth JD. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. *J Thorac Oncol* 4: 1555–1560, 2009.
226. Spigel DR, Hainsworth JD, Gandhi JG, Gian VG, Peyton JD, West-Osterfield K, Clark BL, Vazquez ER, Jones SF, Burris HA, and Greco FA. A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer. *J Thorac Oncol* 5: 862–866, 2010.
227. Spigel DR, Hainsworth JD, Simons L, Meng C, Burris HA, 3rd, Yardley DA, Grapski R, Schreeder M, Mallidi PV, and Greco FA. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: A phase II trial of the Minnie Pearl Cancer Research Network. *J Thorac Oncol* 2: 854–861, 2007.
228. Sprangers MA, Cull A, Bjordal K, Groenvold M, and Aaronson NK. The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: Guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life. *Qual Life Res* 2: 287–295, 1993.
229. Stathopoulos GP, Tsavdaridis D, Malamos NA, Rigatos SK, Kosmas C, Pergantas N, Stathopoulos JG, and Xynotroulas J. Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: A phase II study. *Cancer Chemother Pharmacol* 56: 487–491, 2005.
230. Stone P, Hardy J, Broadley K, Tookman AJ, Kurowska A, and A'Hern R. Fatigue in advanced cancer: A prospective controlled cross-sectional study. *Br J Cancer* 79: 1479–1486, 1999.
231. Stone P, Richards M, A'Hern R, and Hardy J. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. *Ann Oncol* 11: 561–567, 2000.
232. Stone RM, DeAngelo DJ, Janosova A, Galinsky I, Canning C, Ritz J, and Soiffer RJ. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. *Am J Hematol* 83: 771–777, 2008.
233. Stromgren AS, Goldschmidt D, Groenvold M, Petersen MA, Jensen PT, Pedersen L, Hoermann L, Helleberg C, and Sjogren P. Self-assessment in cancer patients referred to palliative care: A study of feasibility and symptom epidemiology. *Cancer* 94: 512–520, 2002.
234. Sugarbaker PH. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer. *Curr Opin Obstet Gynecol* 21: 15–24, 2009.
235. Supinski GS and Callahan LA. Free radical-mediated skeletal muscle dysfunction in inflammatory conditions. *J Appl Physiol* 102: 2056–2063, 2007.
236. Swain SM, Whaley FS, and Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. *Cancer* 97: 2869–2879, 2003.
237. Takemura G and Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. *Prog Cardiovasc Dis* 49: 330–352, 2007.
238. Tangpong J, Cole MP, Sultana R, Joshi G, Estus S, Vore M, St CW, Ratanachaiyavong S, St Clair DK, and Butterfield DA. Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. *Neurobiol Dis* 23: 127–139, 2006.
239. Tew WP, Radovich D, O'Reilly E, Schwartz G, Schrag D, Saltz LB, Kelsen DP, Kepler S, and Ilson DH. Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. *Invest New Drugs* 27: 366–373, 2009.
240. Tewey KM, Rowe TC, Yang L, Halligan BD, and Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. *Science* 226: 466–8, 1984.
241. Tian Q, Katz AM, and Kim DH. Effects of azumolene on doxorubicin-induced Ca²⁺ release from skeletal and cardiac muscle sarcoplasmic reticulum. *Biochim Biophys Acta* 1094: 27–34, 1991.
242. Timolati F, Ott D, Pentassuglia L, Giraud MN, Perriard JC, Suter TM, and Zuppinger C. Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. *J Mol Cell Cardiol* 41: 845–854, 2006.
243. Timur M, Akbas SH, and Ozben T. The effect of topotecan on oxidative stress in MCF-7 human breast cancer cell line. *Acta Biochim Pol* 52: 897–902, 2005.
244. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, and Schlattner U. New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics. *J Mol Cell Cardiol* 41: 389–405, 2006.
245. Tozer RG, Tai P, Falconer W, Ducruet T, Karabadjian A, Bounous G, Molson JH, and Droge W. Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy. *Antioxid Redox Signal* 10: 395–402, 2008.
246. Tsavaris N, Kosmas C, Skopelitis H, Dimitrakopoulos A, Kopterides P, Bougas D, Stravodimos K, Mitropoulos D, Alamanis C, and Giannopoulos A. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: An open label phase II study. *J Chemother* 17: 441–448, 2005.

247. Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, and Kurzrock R. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. *Cancer Chemother Pharmacol* 66: 1087–1093, 2010.
248. Turner-Gomes SO, Lands LC, Halton J, Hanning RM, Heigenhauser GJ, Pai M, and Barr R. Cardiorespiratory status after treatment for acute lymphoblastic leukemia. *Med Pediatr Oncol* 26: 160–165, 1996.
249. Unverferth DV, Jagadeesh JM, Unverferth BJ, Magorien RD, Leier CV, and Balcerzak SP. Attempt to prevent doxorubicin-induced acute human myocardial morphologic damage with acetylcysteine. *J Natl Cancer Inst* 71: 917–920, 1983.
250. Usta Y, Ismailoglu UB, Bakaloglu A, Orhan D, Besbas N, Sahin-Erdemli I, and Ozen S. Effects of pentoxifylline in adriamycin-induced renal disease in rats. *Pediatr Nephrol* 19: 840–843, 2004.
251. Valerio MR, Tagliaferri P, Raspagliesi F, Fulfaro F, Badalamenti G, Arcaro C, Cicero G, Russo A, Venuta S, Guarneri G, and Gebbia N. A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma. *Int J Gynecol Cancer* 16 Suppl 1: 79–85, 2006.
252. Van der Speeten K, Stuart OA, Mahteme H, and Sugarbaker PH. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. *Cancer Chemother Pharmacol* 63: 799–805, 2009.
253. van Norren K, van Helvoort A, Argiles JM, van Tuijl S, Arts K, Gorselink M, Laviano A, Kegler D, Haagsman HP, and van der Beek EM. Direct effects of doxorubicin on skeletal muscle contribute to fatigue. *Br J Cancer* 100: 311–314, 2009.
254. Van Vleet JF and Ferrans VJ. Clinical and pathologic features of chronic adriamycin toxicosis in rabbits. *Am J Vet Res* 41: 1462–1469, 1980.
255. Villani F, Busia A, Villani M, Laffranchi A, Viviani S, and Bonfante V. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radiochemotherapy for Hodgkin's disease. *Anticancer Res* 29: 777–783, 2009.
256. Villani F, Galimberti M, Monti E, Piccinini F, Lanza E, Rozza A, Favalli L, Poggi P, and Zunino F. Effect of glutathione and N-acetylcysteine on *in vitro* and *in vivo* cardiac toxicity of doxorubicin. *Free Radic Res Commun* 11: 145–151, 1990.
257. Vincenzi B, Santini D, Rabitti C, Coppola R, Beomonte Zobel B, Trodella L, and Tonini G. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: A single centre phase II trial. *Br J Cancer* 94: 792–797, 2006.
258. Vodermaier A. Breast cancer treatment and cognitive function: The current state of evidence, underlying mechanisms and potential treatments. *Womens Health (Lond Engl)* 5: 503–516, 2009.
259. Vrdoljak AL, Berend S, Zeljezic D, Piljac-Zegarac J, Plestina S, Kuca K, Radic B, Mladinic M, and Kopjar N. Irinotecan side effects relieved by the use of HI-6 oxime: *In vivo* experimental approach. *Basic Clin Pharmacol Toxicol* 105: 401–409, 2009.
260. Wajant H, Pfizenmaier K, and Scheurich P. Tumor necrosis factor signaling. *Cell Death Differ* 10: 45–65, 2003.
261. Wang GW, Klein JB, and Kang YJ. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes. *J Pharmacol Exp Ther* 298: 461–468, 2001.
262. Waters SH, Gillibrand A, Berry H, Kumar S, Velikova G, Dodwell DJ, and Perren TJ. Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer. *Cancer Chemother Pharmacol* 64: 407–412, 2009.
263. Weiss RB. The anthracyclines: Will we ever find a better doxorubicin? *Semin Oncol* 19: 670–686, 1992.
264. Wessner B, Strasser EM, Koitz N, Schmuckenschlager C, Unger-Manhart N, and Roth E. Green tea polyphenol administration partly ameliorates chemotherapy-induced side effects in the small intestine of mice. *J Nutr* 137: 634–640, 2007.
265. William WN, Jr., Lee JL, Shin DM, Hong WK, Liu S, Lee JJ, Lippman SM, Khuri FR, and Kim ES. Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. *Am J Clin Oncol* 32: 15–19, 2009.
266. William WN, Jr., Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, and Glisson BS. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. *Cancer* 116: 2409–2415, 2010.
267. Wirtschafter JD and McLoon LK. Long-term efficacy of local doxorubicin chemomyectomy in patients with blepharospasm and hemifacial spasm. *Ophthalmology* 105: 342–346, 1998.
268. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, Vohnhof S, Bickeboller H, Toliat MR, Suk EK, Tzvetkov M, Kruger A, Seifert S, Kloess M, Hahn H, Loeffler M, Nurnberg P, Pfreundschuh M, Trumper L, Brockmoller J, and Hasenfuss G. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. *Circulation* 112: 3754–3762, 2005.
269. Wright MJ, Halton JM, Martin RF, and Barr RD. Long-term gross motor performance following treatment for acute lymphoblastic leukemia. *Med Pediatr Oncol* 31: 86–90, 1998.
270. Wu HS and McSweeney M. Assessing fatigue in persons with cancer: An instrument development and testing study. *Cancer* 101: 1685–1695, 2004.
271. Xiong Y, Liu X, Lee CP, Chua BH, and Ho YS. Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase. *Free Radic Biol Med* 41: 46–55, 2006.
272. Yamada K, Sugiyama S, Kosaka K, Hayakawa M, and Ozawa T. Early appearance of age-associated deterioration in mitochondrial function of diaphragm and heart in rats treated with doxorubicin. *Exp Gerontol* 30: 581–593, 1995.
273. Yamamoto Y, Hoshino Y, Ito T, Nariai T, Mohri T, Obana M, Hayata N, Uozumi Y, Maeda M, Fujio Y, and Azuma J. Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes. *Cardiovasc Res* 79: 89–96, 2008.
274. Yamanaka S, Tatsumi T, Shiraishi J, Mano A, Keira N, Matoba S, Asayama J, Fushiki S, Fliss H, and Nakagawa M. Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes. *J Am Coll Cardiol* 41: 870–878, 2003.
275. Yavuzsen T, Davis MP, Ranganathan VK, Walsh D, Siemionow V, Kirkova J, Khoshknabi D, Lagman R, LeGrand

- S, and Yue GH. Cancer-related fatigue: Central or peripheral? *J Pain Symptom Manage* 38: 587–596, 2009.
276. Yen HC, Oberley TD, Vichitbandha S, Ho YS, and St Clair DK. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. *J Clin Invest* 98: 1253–1260, 1996.
 277. Yong WP, Desai AA, Innocenti F, Ramirez J, Shepard D, Kobayashi K, House L, Fleming GF, Vogelzang NJ, Schilsky RL, and Ratain MJ. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. *Cancer Chemother Pharmacol* 60: 811–819, 2007.
 278. Zauderer M, Patil S, and Hurria A. Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. *Breast Cancer Res Treat* 117: 205–210, 2009.
 279. Zellars RC, Stearns V, Frassica D, Asrari F, Tsangaris T, Myers L, DiPasquale S, Lange JR, Jacobs LK, Emens LA, Armstrong DK, Fetting JH, Garrett-Mayer E, Davidson NE, and Wolff AC. Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. *J Clin Oncol* 27: 2816–2822, 2009.
 280. Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, and Ryan DP. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. *Oncologist* 10: 392–398, 2005.
 281. Ziotopoulos P, Androulakis N, Mylonaki E, Chandrinou V, Zachariadis E, Boukovinas I, Agelidou A, Kentepozidis N, Ignatiadis M, Vossos A, and Georgoulas V. Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: A multicentre phase II study. *Lung Cancer* 50: 115–122, 2005.
 282. Zorzato F, Salviati G, Facchinetti T, and Volpe P. Doxorubicin induces calcium release from terminal cisternae of skeletal muscle. A study on isolated sarcoplasmic reticulum

and chemically skinned fibers. *J Biol Chem* 260: 7349–7355, 1985.

Address correspondence to:

Dr. Laura A.A. Gilliam
Department of Physiology
University of Kentucky
800 Rose Street, MS-508
Lexington, KY 40536-0298

E-mail: laura.ashley@uky.edu

Date of first submission to ARS Central, February 28, 2011;
date of acceptance, April 3, 2011.

Abbreviations Used

CAT = catalase
CTCAE = National Cancer Institute Common
Toxicity Criteria for Adverse Events
EORTC QLQ-C30 = European Organization for Research
and Treatment of Cancer QLQ-C30
GpX = glutathione peroxidase
GSH = glutathione
NAC = N-acetylcysteine
NCI = National Cancer Institute
NSCL = non-small cell lung
QOL = quality of life
ROS = reactive oxygen species
SCL = small cell lung
SOD = superoxide dismutase
SR = sarcoplasmic reticulum
TNF = tumor necrosis factor-alpha
TNFR1 = TNF receptor subtype 1

This article has been cited by:

1. Reid Hayward, David Hydock, Noah Gibson, Stephanie Greufe, Eric Bredahl, Traci Parry. 2012. Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function. *Journal of Physiology and Biochemistry* . [\[CrossRef\]](#)
2. T Thirumalai, S Viviyan Therasa, EK Elumalai, E David. 2011. Intense and exhaustive exercise induce oxidative stress in skeletal muscle. *Asian Pacific Journal of Tropical Disease* **1**:1, 63-66. [\[CrossRef\]](#)